Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients.
Critically ill patients
Meropenem
PBPK/PD
PK-Sim
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 08 2024
20 08 2024
Historique:
received:
11
01
2024
accepted:
06
06
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
This study aimed to develop a physiologically based pharmacokinetic/pharmacodynamic model (PBPK/PD) of meropenem for critically ill patients. A PBPK model of meropenem in healthy adults was established using PK-Sim software and subsequently extrapolated to critically ill patients based on anatomic and physiological parameters. The mean fold error (MFE) and geometric mean fold error (GMFE) methods were used to compare the differences between predicted and observed values of pharmacokinetic parameters C
Identifiants
pubmed: 39164261
doi: 10.1038/s41598-024-64223-0
pii: 10.1038/s41598-024-64223-0
doi:
Substances chimiques
Meropenem
FV9J3JU8B1
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19269Subventions
Organisme : Seedling Engineering project of Sichuan Science and Technology Department
ID : 2022JDRC0145
Informations de copyright
© 2024. The Author(s).
Références
Huttner, B. et al. 2019 community-acquired pneumonia treatment guidelines: There is a need for a change toward more parsimonious antibiotic use. Am. J. Respir. Crit. Care Med. 201(10), 1315–1316 (2020).
pubmed: 32069065
pmcid: 7233347
doi: 10.1164/rccm.201911-2226LE
Wunderink, R. G. et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 21(2), 213–225 (2021).
pubmed: 33058798
doi: 10.1016/S1473-3099(20)30731-3
Roberts, J. A. et al. Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. Lancet Infect. Dis. 14(6), 498–509 (2014).
pubmed: 24768475
pmcid: 4181663
doi: 10.1016/S1473-3099(14)70036-2
Roger, C. B. Louart, beta-lactams toxicity in the intensive care unit: An underestimated collateral damage?. Microorganisms 9(7), 1505 (2021).
pubmed: 34361942
pmcid: 8306322
doi: 10.3390/microorganisms9071505
Grimstein, M. et al. Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and drug administration’s office of clinical pharmacology. J. Pharm. Sci. 108(1), 21–25 (2019).
pubmed: 30385284
doi: 10.1016/j.xphs.2018.10.033
Jin, Y. W. & Ma, Y. M. Progress in methodology of establishing physiologically based pharmacokinetic models. Yao Xue Xue Bao 49(1), 16–22 (2014).
pubmed: 24783500
Nicolau, D. P. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother. 9(4), 292–296 (2003).
pubmed: 14691648
doi: 10.1007/s10156-003-0279-X
Pelkonen, O. et al. Local kinetics and dynamics of xenobiotics. Crit. Rev. Toxicol. 38(8), 697–720 (2008).
pubmed: 18686076
doi: 10.1080/10408440802194931
Martins, F. S. et al. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. Br. J. Clin. Pharmacol. 87(3), 1012–1023 (2021).
pubmed: 32638408
doi: 10.1111/bcp.14456
Ramsdell, J., Narsavage, G. L. & Fink, J. B. Management of community-acquired pneumonia in the home: An American college of chest physicians clinical position statement. Chest 127(5), 1752–1763 (2005).
pubmed: 15888856
doi: 10.1378/chest.127.5.1752
Economou, C. et al. Impact of beta-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int. J. Antimicrob. Agents 49(5), 589–594 (2017).
pubmed: 28341612
doi: 10.1016/j.ijantimicag.2017.01.009
Goncalves-Pereira, J. & Povoa, P. Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of beta-lactams. Crit. Care 15(5), R206 (2011).
pubmed: 21914174
pmcid: 3334750
doi: 10.1186/cc10441
de Stoppelaar, F. et al. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J. Antimicrob. Chemother. 46(1), 150–151 (2000).
pubmed: 10882710
doi: 10.1093/jac/46.1.150
Jaruratanasirikul, S., Sriwiriyajan, S. & Punyo, J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob. Agents Chemother. 49(4), 1337–1339 (2005).
pubmed: 15793108
pmcid: 1068632
doi: 10.1128/AAC.49.4.1337-1339.2005
Liebchen, U. et al. The ONTAI study—A survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. J. Crit. Care 60, 260–266 (2020).
pubmed: 32932111
doi: 10.1016/j.jcrc.2020.08.027
Gatti, M. & Pea, F. Continuous versus intermittent infusion of antibiotics in gram-negative multidrug-resistant infections. Curr. Opin. Infect. Dis. 34(6), 737–747 (2021).
pubmed: 34261906
doi: 10.1097/QCO.0000000000000755
Song, X. et al. Is Meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? A pharmacokinetic/pharmacodynamic modeling with monte carlo simulation. Front. Microbiol. 10, 2777 (2019).
pubmed: 31849910
pmcid: 6895071
doi: 10.3389/fmicb.2019.02777
Taccone, F. S. et al. Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob. Agents Chemother. 56, 2129–2131 (2012).
pubmed: 22290984
pmcid: 3318384
doi: 10.1128/AAC.06389-11
Rubino, C. M. et al. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.02103-17 (2018).
doi: 10.1128/AAC.02103-17
pubmed: 29588353
pmcid: 5971579
Kelly, H. C., Hutchison, M. & Haworth, S. J. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J. Antimicrob. Chemother. 36, 35–41 (1995).
pubmed: 8543497
doi: 10.1093/jac/36.suppl_A.35
Craig, W. A. The pharmacology of meropenem, a new carbapenem antibiotic. Clin. Infect. Dis. 24(2), S266–S275 (1997).
pubmed: 9126702
doi: 10.1093/clinids/24.Supplement_2.S266
Wise, R. et al. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob. Agents Chemother. 34(8), 1515–1517 (1990).
pubmed: 2221860
pmcid: 171864
doi: 10.1128/AAC.34.8.1515
Jones, H. K. et al. A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes. Eur. J. Drug Metab. Pharmacokinet. 22(3), 193–199 (1997).
pubmed: 9358198
doi: 10.1007/BF03189806
Jaruratanasirikul, S. & Sriwiriyajan, S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J. Antimicrob. Chemother. 52(3), 518–521 (2003).
pubmed: 12917242
doi: 10.1093/jac/dkg378
Bax, R. P. et al. The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24, 311–320 (1989).
pubmed: 2808215
doi: 10.1093/jac/24.suppl_A.311
Harrison, M. P. et al. The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother. 24, 265–277 (1989).
pubmed: 2808212
doi: 10.1093/jac/24.suppl_A.265
Burman, L. A. et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother. 27(2), 219–224 (1991).
pubmed: 2055812
doi: 10.1093/jac/27.2.219
Ljungberg, B. & Nilsson-Ehle, I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob. Agents Chemother. 36(7), 1437–1440 (1992).
pubmed: 1510440
pmcid: 191600
doi: 10.1128/AAC.36.7.1437
Leroy, A. et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob. Agents Chemother. 36(12), 2794–2798 (1992).
pubmed: 1482147
pmcid: 245547
doi: 10.1128/AAC.36.12.2794
Krueger, W. A. et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49(5), 1881–1889 (2005).
pubmed: 15855510
pmcid: 1087638
doi: 10.1128/AAC.49.5.1881-1889.2005
Dandekar, P. K. et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 23(8), 988–991 (2003).
pubmed: 12921245
doi: 10.1592/phco.23.8.988.32878
Nilsson-Ehle, I. et al. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10(2), 85–88 (1991).
pubmed: 1864280
doi: 10.1007/BF01964413
Wenzler, E. & Scoble, P. J. An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam. Infect. Dis. Ther. 9(4), 769–784 (2020).
pubmed: 33025557
pmcid: 7680462
doi: 10.1007/s40121-020-00344-z
Mallalieu, N. L. et al. Safety and pharmacokinetic characterization of nacubactam, a novel beta-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.02229-19 (2020).
doi: 10.1128/AAC.02229-19
pubmed: 32041717
pmcid: 7179653
Roberts, J. A. et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 64(1), 142–150 (2009).
pubmed: 19398460
doi: 10.1093/jac/dkp139
Kitzes-Cohen, R. et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int. J. Antimicrob. Agents 19(2), 105–110 (2002).
pubmed: 11850162
doi: 10.1016/S0924-8579(01)00474-5
Li, C. et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46(10), 1171–1178 (2006).
pubmed: 16988206
doi: 10.1177/0091270006291035
Frippiat, F. et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: The PROMESSE study. J. Antimicrob. Chemother. 70(1), 207–216 (2015).
pubmed: 25216821
doi: 10.1093/jac/dku354
Lee, D. H. et al. Population pharmacokinetics of meropenem in critically ill korean patients and effects of extracorporeal membrane oxygenation. Pharmaceutics https://doi.org/10.3390/pharmaceutics13111861 (2021).
doi: 10.3390/pharmaceutics13111861
pubmed: 35056977
pmcid: 8778970
Kothekar, A. T. et al. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against Gram-negative bacteria. Ann. Intensive Care 10(1), 4 (2020).
pubmed: 31925610
pmcid: 6954163
doi: 10.1186/s13613-019-0622-8
Benitez-Cano, A. et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: A randomized pharmacokinetic trial. Crit. Care 24(1), 55 (2020).
pubmed: 32066497
pmcid: 7026992
doi: 10.1186/s13054-020-2763-4
Thalhammer, F. et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 43(4), 523–527 (1999).
pubmed: 10350382
doi: 10.1093/jac/43.4.523
Lodise, T. P. et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob. Agents Chemother. 55(4), 1606–1610 (2011).
pubmed: 21300830
pmcid: 3067164
doi: 10.1128/AAC.01330-10
Trang, M. et al. Population pharmacokinetics of meropenem and vaborbactam based on data from noninfected subjects and infected patients. Antimicrob. Agents Chemother. 65(9), e0260620 (2021).
pubmed: 34097490
doi: 10.1128/AAC.02606-20